Tenderwize
Back to tender search

Pharmaceuticals with active ingredient Denosumab

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline May 30, 2028 · 557 days left·Open·Supplies
Original notice title

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Denosumab (ATC: M05BX04)

57/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Why this score?

Opportunity

57 / 100

Complexity

48 / 100

Risk factors

The notice provides no estimated value, expected quantities, reimbursement assumptions, or pricing terms, making commer...

The notice refers to participation conditions but does not specify them in the available data. The XML contains coded e...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK Sachsen - Anhalt
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
May 30, 2028

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Conclusion of non-exclusive rebate agreements under §130a(8) SGB V.
  • Supply-related scope concerning finished medicinal products containing Denosumab, ATC M05BX04.
Show full summary

Open-house model for non-exclusive rebate agreements under §130a(8) SGB V covering finished medicinal products containing Denosumab (ATC M05BX04). Any pharmaceutical company or consortium meeting the participation conditions may conclude an agreement on identical terms, without exclusivity or individual negotiations. The earliest contract start is 2026-08-01 and all agreements end on 2028-07-31. Contract volume and pricing information are not provided. The notice states that this is not a public contract under German procurement law. Procurement documents must be requested from the buyer and were not analyzed.

Risks

The notice provides no estimated value, expected quantities, reimbursement assumptions, or pricing terms, making commer...

The notice refers to participation conditions but does not specify them in the available data. The XML contains coded e...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • The participant must be a pharmaceutical company or a consortium of pharmaceutical companies.

Administrative

  • Participation documents must be requested from the stated buyer contact.
  • The participation documents must be completed in full and signed before an agreement can be concluded.

Buyer

Location

Magdeburg, DEU

Buyer profile

Open profile

Identifier

DE258393558

Activity

Health

Lots (1)

LOT-0001

Denosumab medicinal products

Non-exclusive rebate agreements for finished medicinal products containing Denosumab (ATC M05BX04) under an open-house model. Agreements are available to every pharmaceutical company meeting the participation conditions, on identical terms and without individual negotiations. The agreement may be terminated according to its contractual provisions if the buyer later awards exclusive contracts for the substance.

SuppliesEU fundedElectronic submission

Location

DEE03, Germany

Duration

2 YEAR

Category

Pharmaceutical products

Deadline

Deadline May 30, 2028

Procurement Details

Publication date
03 Jun 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
385290-2026

Documents (1)

Similar tenders

Cookies & Privacy

With your consent, we use Google Analytics, Microsoft Clarity (session recordings) and Google Ads cookies to understand how Tenderwize is used and to measure our advertising. You can change your choice at any time via “Cookie Settings” in the footer. Cookie Policy · Privacy Policy